De Wolf-Peeters C, Pittaluga S
University Hospitals, K.U. Leuven, Department of Pathology II, Belgium.
Curr Opin Oncol. 1996 Sep;8(5):366-70. doi: 10.1097/00001622-199609000-00005.
The proposal from the International Lymphoma Study Group (ILSG) of a new classification for lymphoid neoplasm, known as the Revised European-American Lymphoma (REAL) classification, has been received by clinicians and pathologists with mixed reactions. Numerous letters, editorials, and abstracts have been published in the past year praising and criticizing this proposal. The feasibility as well as the clinical validity of the ILSG proposal has been tested in retrospective studies based on large multicenter trials, and a large multi-institutional effort to prove or disprove the validity of the REAL classification was undertaken by the International Non Hodgkin's Lymphoma Classification Project. All these studies seems to confirm the usefulness of the REAL classification. Besides the overall evaluation of the ILSG proposal, the clinical validity of the newly defined entities (eg, mantle cell lymphoma, marginal zone cell lymphoma) has been shown by these and other retrospective studies. However, the main objection of clinicians remains the lack of grouping of lymphoma entities according to their clinical behavior, which we as pathologists believe to be the clinician's task.
国际淋巴瘤研究组（ILSG）提出的一项针对淋巴样肿瘤的新分类，即修订的欧美淋巴瘤（REAL）分类，临床医生和病理学家对此反应不一。在过去一年里，发表了许多信件、社论和摘要，对该提议既有赞扬也有批评。ILSG提议的可行性及临床有效性已在基于大型多中心试验的回顾性研究中得到检验，国际非霍奇金淋巴瘤分类项目开展了一项大型多机构工作，以证明或反驳REAL分类的有效性。所有这些研究似乎都证实了REAL分类的有用性。除了对ILSG提议的总体评估外，这些及其他回顾性研究还表明了新定义实体（如套细胞淋巴瘤、边缘区细胞淋巴瘤）的临床有效性。然而，临床医生的主要反对意见仍然是淋巴瘤实体未根据其临床行为进行分组，而我们病理学家认为这是临床医生的任务。
